P
BIO icon

Pitcairn’s Bio-Rad Laboratories Class A BIO Stock Holding History

Pitcairn’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-520
Closed -$393K – 612
2021
Q4 		$393K Sell
520
-121
-19% -$90.6K 0.03% 433
2021
Q3 		$478K Sell
641
-455
-42% -$341K 0.03% 362
2021
Q2 		$706K Sell
1,096
-738
-40% -$449K 0.05% 261
2021
Q1 		$1.05M Buy
1,834
+160
+10% +$94.8K 0.07% 191
2020
Q4 		$976K Buy
1,674
+151
+10% +$86K 0.07% 185
2020
Q3 		$785K Buy
1,523
+1,076
+241% +$545K 0.07% 189
2020
Q2 		$202K Buy
+447
New +$197K 0.02% 469

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Pitcairn's BIO Position: Q1 2022 in Review

Pitcairn sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2022, closing a stake of 520 shares — an estimated $393K sold.

Pitcairn first reported a position in BIO in Q2 2020 and held it in 7 quarters. The position peaked at $1.05M in Q1 2021. 514 funds tracked by Wall St. Rank hold BIO as of Q1 2022.

  • Pitcairn reported no remaining Bio-Rad Laboratories Class A position as of Q1 2022 after selling out during the quarter.
  • Pitcairn sold 520 Bio-Rad Laboratories Class A shares in Q1 2022, an estimated $393K.
  • Pitcairn first reported a position in Bio-Rad Laboratories Class A in Q2 2020 and held it in 7 quarters.
  • Pitcairn's Bio-Rad Laboratories Class A position peaked at $1.05M in Q1 2021.
  • 514 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2022.

Based on Pitcairn's 13F filing for Q1 2022, filed 12 May 2022.